Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00142155 · ClinicalTrials.gov registry record · NA
Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia
A NA study, sponsored by Dana-Farber Cancer Institute.
- Completed
- Registry status
- NA
- Development phase
- 300
- Enrollment target
NCT00142155 is a NA study that has completed, run by Dana-Farber Cancer Institute. The registered enrollment target is 300 participants.
The verdict
NCT00142155, a NA study, has completed, sponsored by Dana-Farber Cancer Institute.
- COMPLETED
- Registry status
- NA
- Development phase
- 300 participants
- Enrollment target
Study Summary
The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
Interventions
- DRUG Rituximab
- DRUG monoclonal antibodies
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 300 participants |
| Start Date | 2002-01 |
| Est. Completion | 2007-03 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00142155
The ClinicalTrials.gov registry entry for NCT00142155 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 300 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Dana-Farber Cancer Institute, which has 781 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Rituximab is the first listed.
NCT00142155 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00142155 about?
NCT00142155 is a clinical study titled "Correlation of FC Gamma RIIIA Receptor Response in Patients With Waldenstrom's Macroglobulinemia". The purpose of this study is to determine if the type of Fc gamma RIIIa receptor that a particular patient's immune cells possess influences how they respond to rituximab and other monoclonal antibodies.
What is the current status of trial NCT00142155?
This trial is currently completed. It is a NA study. The enrollment target is 300 participants. The study started on 2002-01. Estimated completion is 2007-03.
What interventions are being tested in trial NCT00142155?
The interventions under investigation include: Rituximab (DRUG), monoclonal antibodies (DRUG).
Who is sponsoring clinical trial NCT00142155?
This trial is sponsored by Dana-Farber Cancer Institute, which has 781 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.